
Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

